Macrogen adopts Roche's next-gen platform to speed up genome sequencing
Predicted impact: Low· Actual: +2.9% vs sector, volume 0.9× normal (5 trading days)
Sequencing platform adoption is a small commercial partnership with no size given.
Macrogen마크로젠
038290 · KOSDAQ · ₩038290 · 마크로젠
₩11,050▲ ₩40 (0.36%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −27.78%
- Market cap
- ₩120B
- Enterprise value
- ₩155B
- P/E
- 11.6×
- P/B
- 0.8×
- Dividend yield
- 4.5%
- ROE
- 6.6%
- Net margin
- 5.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−47.1% from the high
₩10,440Today: ₩10,900 – ₩11,200₩20,900
Returns
- 1W−4.7%
- 1M−8.6%
- 3M−2.6%
- 6M−34.6%
- YTD−34.5%
- 1Y−27.8%
- Volume today
- 9,227
- 0.5× the 20-day average
- Traded today
- ₩102M
- Listed shares
- 10,841,400
- EPS (12 months)
- ₩950
- Earnings yield 8.6%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- MomentumWeak-6.6% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Macrogen stock overview
Macrogen (마크로젠, KRX: 038290) is listed on KOSDAQ, in the Business services sector. Macrogen is a Korean precision medicine biotechnology company founded in 1997 that specializes in genome analysis. Its shares closed at ₩11,050 on Oct 27, 2026, up 0.36% on the day, giving it a market value of ₩120B.
Key facts
- Market cap
- ₩120B
- Sector
- Business services
- Latest price change
- +0.36%
- As of
- Oct 27, 2026
- Main business
- Macrogen is a Korean precision medicine biotechnology company founded in 1997 that specializes in genome analysis.
Quick answers about Macrogen
- What does Macrogen do?
- Macrogen is a Korean precision medicine biotechnology company founded in 1997 that specializes in genome analysis. Its main business is genome sequencing services covering humans, animals, plants, viruses and bacteria, using both CES and next-generation sequencing technologies, and it also offers Oligo synthesis, Microarray analysis, genetically modified mouse production and proteomics analysis services to researchers and clinical customers, operating through genome centers in major cities worldwide.
- What is the market cap of Macrogen?
- The market capitalisation of Macrogen was ₩120B at the close on Oct 27, 2026.
- Who are the largest shareholders of Macrogen?
- According to the latest official filings, the largest reported holders are Seo Jeong-seon (20.13%, as of Jun 25, 2026); National Pension Service (4.56%, as of Dec 31, 2025); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.35%, as of Jul 31, 2026).
- When is the next earnings report from Macrogen?
- Korean companies rarely announce results dates in advance. Based on when Macrogen filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Macrogen?
- Yes. The National Pension Service held 4.56% of Macrogen shares as of Dec 31, 2025.
Company profile
Macrogen is a Korean precision medicine biotechnology company founded in 1997 that specializes in genome analysis. Its main business is genome sequencing services covering humans, animals, plants, viruses and bacteria, using both CES and next-generation sequencing technologies, and it also offers Oligo synthesis, Microarray analysis, genetically modified mouse production and proteomics analysis services to researchers and clinical customers, operating through genome centers in major cities worldwide.
Written by AI from the company's latest annual report.
- Korean name
- 마크로젠
- Sector
- Business services
- Themes
- Biotech (new drugs)
- CEO
- 서정선, 김창훈, 이응룡 (각자 대표이사)
- Founded
- Jun 1997
- Listed
- Feb 2000
- Listed shares
- 10,841,400
- Fiscal year ends
- Month 12
- Website
- www.macrogen.com
Similar companies
- S-1012750 · ₩3.6T₩95,300+2.14%
- Cheil Worldwide030000 · ₩2.2T₩19,010−0.83%
- Doosan Tesna131970 · ₩1.9T₩97,100+1.78%
- Lotte Tour Development032350 · ₩821B₩10,300+1.98%
- Soulbrain Holdings036830 · ₩772B₩37,650+4.73%
- Innocean Worldwide214320 · ₩694B₩17,360+0.52%
- Korea Ratings034950 · ₩458B₩100,8000.00%
- GC005250 · ₩425B₩9,030−0.66%
Recent news
Recent filings
See all- Insider shareholding reportOct 1, 2026
- Amended: Major sales or supply contractSep 10, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportJun 25, 2026
- 5%+ holding reportMay 29, 2026
Titles in Korean until English translations are added.
Also known as: Macrogen / 마크로젠 / 038290 / KRX:038290
Source: KRX statistical information